Clinical trials: Bladder Tumors
Bladder Cancer
Phase II Study of Oxaliplatin and Taxotere in Metastatic Bladder Cancer
To combine oxaliplatin and taxotere in patients who have had prior cisplatin therapy in bladder cancer.
- Trial name
- NCT00186277
- Testing
- Oxaliplatin, Taxotere
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Stanford University
Bladder Cancer
Outcomes of High-risk Non-muscle Invasive Bladder Cancer Treated With Blue Light Resection
Comparing white-light cystoscopy (WLC) and blue-light cystoscopy (BLC) in TURBT for high risk (HR) non-muscle invasive bladder cancer (NMIBC) patients is crucial to determine the most effective method for reducing residual…
- Trial name
- NCT06525571
- Testing
- Cysview, Karl Storz D-Light C Photodynamic Diagnostic (PDD) system
- Where
- 2 sites in United States
- Volunteers
- 200 people
- Sponsor
- Johns Hopkins University
Urinary Bladder Cancer
Safety and Tolerability of TAR-200 mg in Subjects With Non-Muscle-Invasive Bladder Cancer
The purpose of this study is to determine if TAR-200, an investigational drug-delivery system is safe and tolerable in patients with recurrent low or intermediate risk non-muscle-invasive bladder cancer (NMIBC) between diagnosis…
- Trial name
- NCT02720367
- Testing
- Gemcitabine-Releasing Intravesical System (GemRIS)/TAR-200
- Where
- 2 sites in Netherlands
- Volunteers
- 12 people
- Sponsor
- Taris Biomedical LLC
Bladder Cancer, Prostate Cancer
Robot-assisted Urological Surgeries Using the MicroHand S Robot
A single-blinded, prospective randomized parallel controlled clinical trial is designed and will be conducted from July 2022 to November 2023 (anticipated).
- Conditions
- Bladder Cancer, Prostate Cancer, Renal Cancer
- Trial name
- NCT05462392
- Testing
- robot-assisted surgery
- Where
- China
- Volunteers
- 136 people
- Sponsor
- The Affiliated Hospital of Qingdao University
Non-muscle Invasive Bladder Cancer
Safety and Toxicity Study of Intravesical Instillation of TARA-002 in Adults with High-grade Non-muscle Invasive Bladder Cancer (Phase 1a)
This study is an open-label dose escalation study (Phase 1a) to investigate the safety and toxicity of intravesical treatment of high-grade NMIBC (HGTa or CIS, including CIS with concomitant Ta) after transurethral resection of…
- Trial name
- ADVANCED-1 (NCT05085977)
- Testing
- TARA-002
- Where
- 14 sites in United States, Moldova and 2 more
- Volunteers
- 12 people
- Sponsor
- Protara Therapeutics
Bladder Cancer
Intravesical Thermochemotherapy With Mitomycin-c
To investigate effect of intravesical mitomycin-C(MMC) applied with bladder wall thermotherapy system on reccurrence and progression status of intermediate and high risk non muscle invasive bladder cancer
- Trial name
- NCT03694535
- Testing
- bladder wall thermotherapy with Mitomycin-c
- Where
- Turkey (Türkiye)
- Volunteers
- 44 people
- Sponsor
- TC Erciyes University
Safety Issues
Trimodal Therapy Plus Atezolizumab in Muscle-invasive Bladder Cancer
This is a single arm phase II trial to (1) evaluate safety and toxicity profile of intravenous Atezolizumab (anti-PDL-1) administered in combination with TMT in patients with MIBC, (2) To determine the loco-regional control rate…
- Trial name
- NCT03620435
- Testing
- Atezolizumab
- Where
- Canada
- Volunteers
- 25 people
- Sponsor
- McGill University Health Centre/Research Institute of the McGill University Health Centre
Bladder Cancer
Intracorporeal vs Extracorporeal Urinary Diversion After Robot Assisted Radical Cystectomy
Intracorporeal urinary diversion (ICD) provides superior postoperative outcomes compared to extracorporeal urinary diversion (ECD).
- Trial name
- NCT03469362
- Testing
- Extracorporeal Urinary Diversion, Intracorporal Urinary Diversion
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- University of Miami
Malignant Melanoma, Metastatic, Non Small Cell Lung Cancer Metastatic
Personalized Neo-antigen Vaccine in Advanced Solid Tumors (NeoPepVac)
The primary objective is to assess tolerability and safety of a personalized neo-antigen vaccine containing up to 15 peptides derived from somatic mutation of the individual patient's cancer, with CAF09b as adjuvant.
- Conditions
- Malignant Melanoma, Metastatic, Non Small Cell Lung Cancer Metastatic, Bladder Urothelial Carcinoma, Metastatic
- Trial name
- NeoPepVac (NCT03715985)
- Testing
- EVAX-01-CAF09b
- Where
- 2 sites in Denmark
- Volunteers
- 12 people
- Sponsor
- Herlev Hospital
Bladder Cancer
Adjuvant Nivolumab Following Chemo-Radiation in Localized Muscle-Invasive Bladder Cancer
This is a phase 2, single arm, open label trial to evaluate the rate of failure free survival at 2 years after start of chemoradiation with adjuvant nivolumab in adult subjects who undergo chemoradiation for localized bladder…
- Trial name
- NEXT (NCT03171025)
- Testing
- Nivolumab
- Where
- 2 sites in United States
- Volunteers
- 200 people
- Sponsor
- University of Utah
Cancer
Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain
This is a phase III, randomized, double-blind, placebo-controlled, multicenter study of the clinical response to fentanyl sublingual spray as a treatment for breakthrough cancer pain.
- Trial name
- NCT00538850
- Testing
- Fentanyl sublingual spray
- Where
- United States
- Volunteers
- 130 people
- Sponsor
- INSYS Therapeutics Inc
Prostate Cancer, Urinary Incontinence, Urge
Effects of Urinary Bladder Hypertrophy on Urge Urine Incontinence After Radical Prostatectomy
This study is designed to evaluate men before radical prostatectomy for the incidence of Overactive Bladder (OAB), as well as urge urine incontinence (UUI) development after the surgery.
- Conditions
- Prostate Cancer, Urinary Incontinence, Urge, Incontinence, Prostatectomy
- Trial name
- NCT03061760
- Testing
- Radical prostatectomy, Initial evaluation, Evaluation after 1,3,6,9,12 months
- Volunteers
- 250 people, healthy volunteers welcome
- Sponsor
- Collegium Medicum w Bydgoszczy
Bladder Neoplasms
Mycobacterial Cell Wall-DNA Complex in Treatment of BCG-refractory Patients With Non-muscle Invasive Bladder Cancer
The purpose of this study is to determine the efficacy and safety of intravesical Mycobacterial Cell Wall-DNA Complex (MCC) in patients with non-muscle invasive transitional cell carcinoma (papillary tumors and/or carcinoma in…
- Trial name
- NCT00406068
- Testing
- Mycobacterial cell wall-DNA complex
- Where
- 31 sites in United States, Canada
- Volunteers
- 129 people
- Sponsor
- Bioniche Life Sciences Inc.
Bladder Carcinoma Infiltrating the Muscle of the Bladder Wall, Stage II Bladder Cancer AJCC v8
Avelumab in Combination With Fluorouracil and Mitomycin or Cisplatin and Radiation Therapy in Treating Participants With Muscle-Invasive Bladder Cancer
This phase II trial studies the side effects of avelumab and how well it works in combination with fluorouracil and mitomycin or cisplatin and radiation therapy in treating participants with muscle-invasive bladder cancer.
- Conditions
- Bladder Carcinoma Infiltrating the Muscle of the Bladder Wall, Stage II Bladder Cancer AJCC v8, Stage II Renal Pelvis Cancer AJCC v8, Stage II Ureter Cancer AJCC v8
- Trial name
- NCT03617913
- Testing
- Avelumab, Cisplatin, Fluorouracil
- Where
- 3 sites in United States
- Volunteers
- 2 people
- Sponsor
- Mayo Clinic
Bladder Cancer
Prospective Study of Adjuvant Radiotherapy in High Risk Bladder Cancer.
This prospective interventional study aims at evaluating the safety and efficacy of an adjuvant radiation treatment in cases of muscle-invasive bladder cancer, submitted to radical cystectomy and presenting clinic-pathological…
- Trial name
- Bladder-Aid (NCT03718741)
- Testing
- Radiotherapy +/- CT
- Where
- Italy
- Volunteers
- 7 people
- Sponsor
- Istituto Clinico Humanitas
Muscle-Invasive Bladder Carcinoma
NEO-BLAST: Neoadjuvant Therapy for Bladder Cancer Followed by Active Surveillance vs Treatment
Invasive bladder cancer is managed with neoadjuvant therapy followed by bladder removal (cystectomy). Research shows that approximately 40% of patient will have no remaining cancer left in their bladder after completion of the…
- Trial name
- NEO-BLAST (NCT06537154)
- Testing
- Active Surveillance, Control arm - Definitive bladder treatment
- Where
- Canada
- Volunteers
- 688 people
- Sponsor
- Peter Black
Bladder Cancer
Single Subject Neratinib in Bladder Cancer (NRR)
This study will be a single subject study to evaluate the efficacy of the HER2 kinase inhibitor, neratinib, in a patient with metastatic bladder cancer harboring a HER2-GRB7 gene fusion.
- Trial name
- NCT01956253
- Testing
- Neratinib
- Where
- United States
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Muscle-invasive Bladder Cancer
Impact of Positron Emission Tomography (PET) Imaging in Muscle-invasive Urothelial Carcinoma of the Bladder Staging
Bladder cancer is the fifth most common cancer in Canada and there has been relatively little progress in altering its clinical course over the last three decades.
- Trial name
- PET MUSE (NCT02462239)
- Testing
- Whole-body FDG PET-CT
- Where
- 6 sites in Canada
- Volunteers
- 292 people
- Sponsor
- Ontario Clinical Oncology Group (OCOG)
Bladder Cancer
Effect of Dietary, Lifestyle, and Environmental Factors on Patients With Early-Stage Bladder Cancer
RATIONALE: Learning about the long-term effects of dietary, lifestyle, and environmental factors on the risk of cancer progression and recurrence may help the study of bladder cancer in the future.
- Trial name
- NCT00553566
- Testing
- medical chart review, questionnaire administration, study of socioeconomic and demographic variables
- Where
- United Kingdom
- Volunteers
- 1,600 people
- Sponsor
- University of Birmingham
MIBC, mpMRI
Early Prediction of Neoadjuvant Chemotherapy Response in Bladder Cancer Using Quantitative Multiparametric MRI
Bladder cancer is a prevalent malignancy globally, with muscle-invasive disease having a five-year survival rate below 50%. Neoadjuvant chemotherapy (NAC) before radical cystectomy has shown efficacy for resectable…
- Conditions
- MIBC, mpMRI, NAC
- Trial name
- mpMRI (NCT07202845)
- Testing
- Multiparametric Magnetic Resonance Imaging (mpMRI)
- Where
- Egypt
- Volunteers
- 39 people
- Sponsor
- Assiut University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.